--- title: "Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of \"Moderate Buy\" from Analysts" type: "News" locale: "en" url: "https://longbridge.com/en/news/295316305.md" description: "Vor Biopharma (NASDAQ:VOR) holds a consensus 'Moderate Buy' rating from 11 analysts, with an average 1-year target price of $42.25. Recent analyst actions include Jefferies raising its rating to 'strong-buy' and HC Wainwright reaffirming 'buy'. Institutional investors significantly increased stakes in Q4, with RA Capital Management and Fcpm Iii Services B.V. making substantial purchases. The company reported -$307.61 EPS for the quarter, with forecasts of -2.51 EPS for the current fiscal year." datetime: "2026-08-09T06:44:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295316305.md) - [en](https://longbridge.com/en/news/295316305.md) - [zh-HK](https://longbridge.com/zh-HK/news/295316305.md) generator: "portal-rs" --- # Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Analysts Shares of Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eleven analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $42.25. Get **Vor Biopharma** alerts: A number of equities research analysts recently weighed in on VOR shares. Jefferies Financial Group raised shares of Vor Biopharma to a "strong-buy" rating in a report on Thursday, April 30th. Weiss Ratings upgraded shares of Vor Biopharma from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, June 30th. Wall Street Zen cut shares of Vor Biopharma from a "hold" rating to a "sell" rating in a research report on Saturday, May 16th. Wedbush raised their target price on Vor Biopharma from $15.00 to $18.00 and gave the company a "neutral" rating in a research note on Thursday, May 14th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $31.00 target price on shares of Vor Biopharma in a research report on Monday, May 18th. **View Our Latest Stock Analysis on Vor Biopharma** ## Vor Biopharma Price Performance VOR stock opened at $23.67 on Friday. The stock has a 50-day moving average price of $17.62 and a two-hundred day moving average price of $15.80. Vor Biopharma has a 12-month low of $6.50 and a 12-month high of $50.20. Vor Biopharma (NASDAQ:VOR - Get Free Report) last posted its earnings results on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. As a group, sell-side analysts forecast that Vor Biopharma will post -2.51 earnings per share for the current fiscal year. ## Institutional Investors Weigh In On Vor Biopharma A number of institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. increased its stake in Vor Biopharma by 172.7% during the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company's stock valued at $70,697,000 after purchasing an additional 3,422,697 shares during the last quarter. Fcpm Iii Services B.V. lifted its position in shares of Vor Biopharma by 852.8% in the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company's stock worth $47,315,000 after buying an additional 3,237,714 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new position in shares of Vor Biopharma in the 4th quarter valued at about $33,275,000. Paradigm Biocapital Advisors LP acquired a new position in shares of Vor Biopharma in the 4th quarter valued at about $22,890,000. Finally, NEXTBio Capital Management LP bought a new stake in shares of Vor Biopharma during the 4th quarter valued at about $13,080,000. 97.29% of the stock is currently owned by institutional investors. ## About Vor Biopharma (Get Free Report) Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability. The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). ## See Also - Five stocks we like better than Vor Biopharma - Quantum Earnings Week: Winners and Losers Are Finally Emerging - Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth - Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside - AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Vor Biopharma Right Now? Before you consider Vor Biopharma, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list. While Vor Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [VOR.US](https://longbridge.com/en/quote/VOR.US.md) - [JEF.US](https://longbridge.com/en/quote/JEF.US.md) - [AXON.US](https://longbridge.com/en/quote/AXON.US.md) - [UBER.US](https://longbridge.com/en/quote/UBER.US.md) - [APP.US](https://longbridge.com/en/quote/APP.US.md) ## Related News & Research - [Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update | VOR Stock News](https://longbridge.com/en/news/295545637.md) - [Vor Bio Q2 FY26 net loss narrows to $62.8 million; R&D expenses drop to $25.9 million](https://longbridge.com/en/news/295544536.md) - [Wrap Technologies (NASDAQ: WRAP) Selected to Support Florida Teacher Safety Training Program](https://longbridge.com/en/news/296129490.md) - [Is Wall Street Bullish or Bearish on Cummins Stock?](https://longbridge.com/en/news/296615233.md) - [Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | VOR Stock News](https://longbridge.com/en/news/291592393.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**